Eupraxia Pharmaceuticals Inc
EPRX
查看详细走势图
7.135USD
+0.135+1.93%
交易中 （美东）报价延迟15分钟
361.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.93%
5天
+15.83%
1月
+14.90%
6月
+65.16%
今年开始到现在
+125.08%
1年
+138.63%
查看详细走势图
TradingKey Eupraxia Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Eupraxia Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
买入
评级
12.250
目标均价
+104.17%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Eupraxia Pharmaceuticals Inc亮点
亮点风险
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-6.82，处于3年历史低位
机构加仓
最新机构持股2.23M股，环比增加1.15%
Eupraxia Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Eupraxia Pharmaceuticals Inc简介
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
公司代码EPRX
公司Eupraxia Pharmaceuticals Inc
CEOHelliwell (James A)
网址https://eupraxiapharma.com/home/default.aspx
常见问题
Eupraxia Pharmaceuticals Inc(EPRX)的当前股价是多少？
Eupraxia Pharmaceuticals Inc(EPRX)的当前股价是 7.135。
Eupraxia Pharmaceuticals Inc的股票代码是什么？
Eupraxia Pharmaceuticals Inc的股票代码是EPRX。
Eupraxia Pharmaceuticals Inc股票的52周最高点是多少？
Eupraxia Pharmaceuticals Inc股票的52周最高点是9.880。
Eupraxia Pharmaceuticals Inc股票的52周最低点是多少？
Eupraxia Pharmaceuticals Inc股票的52周最低点是3.960。
Eupraxia Pharmaceuticals Inc的市值是多少？
Eupraxia Pharmaceuticals Inc的市值是361.02M。
Eupraxia Pharmaceuticals Inc的净利润是多少？
Eupraxia Pharmaceuticals Inc的净利润为-25.50M。
现在Eupraxia Pharmaceuticals Inc(EPRX)的股票是买入、持有还是卖出？
根据分析师评级，Eupraxia Pharmaceuticals Inc(EPRX)的总体评级为买入，目标价格为12.250。
Eupraxia Pharmaceuticals Inc(EPRX)股票的每股收益（EPS TTM）是多少
Eupraxia Pharmaceuticals Inc(EPRX)股票的每股收益（EPS TTM）是-0.817。
相关品种
